Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)

Date

09 Sep 2017

Session

Poster display session

Presenters

Charles Rudin

Citation

Annals of Oncology (2017) 28 (suppl_5): v539-v542. 10.1093/annonc/mdx386

Authors

C.M. Rudin1, L. Shen2, M.C. Pietanza2

Author affiliations

  • 1 Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Clinical Research, Merck & Co., Inc., 07033 - Kenilworth/US
More

Resources

Background

Therapeutic options for SCLC remain limited, with EP as the standard first-line chemotherapy regimen. However, patients (pts) with ES-SCLC experience high relapse rates within months after initial therapy. Pembrolizumab, a humanized monoclonal antibody against PD-1, has shown antitumor activity as monotherapy in heavily pretreated pts with PD-L1–positive SCLC in the phase 1b KEYNOTE-028 study. KEYNOTE-604 (ClinicalTrials.gov, NCT03066778) evaluates EP plus either pembrolizumab or placebo (pbo) as first-line therapy for ES-SCLC.

Trial design

In this international, double-blind, phase 3 trial, adults with newly diagnosed ES-SCLC, ECOG PS ≤ 1, and no previous systemic therapy for SCLC are randomized 1:1 to receive either EP plus a 200-mg fixed dose of pembrolizumab intravenously (IV) once every 3 weeks (Q3W) or EP plus pbo IV Q3W. Randomization is stratified by the chosen platinum therapy (carboplatin vs cisplatin), ECOG PS (0 vs 1), and baseline lactate dehydrogenase concentration (≤ upper limit of normal [ULN] vs > ULN). Study treatment includes a total of 4 cycles of EP and 2 y of pembrolizumab/pbo and continues until documented PD, intolerable toxicity, or withdrawal of consent. Pts with a response after 4 cycles of EP plus pbo or pembrolizumab may receive prophylactic cranial irradiation. Pts who complete 2 y of pembrolizumab treatment or stop pembrolizumab for reasons other than PD/intolerability, but subsequently have documented PD, may receive an additional 1 y of pembrolizumab. Tumor response is assessed every 6 wk for 48 wk, and every 9 wk thereafter by RECIST version 1.1 by blinded independent central review. AEs occurring during treatment and 30 d thereafter (90 d for serious AEs) are graded per Common Terminology Criteria for Adverse Events, version 4.0. Primary endpoints are PFS and OS. Secondary endpoints are ORR, duration of response, safety, and patient-reported outcomes. Enrollment is ongoing with a planned enrollment of approximately 430 pts.

Clinical trial identification

NCT03066778; EudraCT Number: 2016-004309-15

Legal entity responsible for the study

Merck & Co., Inc., Kenilworth, NJ, USA

Funding

This research was supported by Merck & Co., Inc., Kenilworth, NJ, USA

Disclosure

C.M. Rudin: Advisory board member: Abbvie, Araxes, BMS, Celgene, G1 Therapeutics, Harpoon, Novartis. L. Shen, M.C. Pietanza: Employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings